Core Insights - AstraZeneca's Imfinzi has received European Commission approval as a perioperative treatment for early gastric and gastroesophageal junction cancers, marking it as the first and only immunotherapy for this indication in the EU [1][7][6] Approval and Clinical Data - The approval is based on the global phase III MATTERHORN study, which showed significant improvements in event-free survival and overall survival [5] - Imfinzi demonstrated a 29% reduction in the risk of disease progression, recurrence, or death compared to chemotherapy alone, and a 22% reduction in the risk of death in the final overall survival analysis [6][7] Market Performance - Year-to-date, AstraZeneca's shares have increased by 4.5%, outperforming the industry growth of 3.7% [3] - Imfinzi is projected to generate $6.1 billion in sales by 2025, reflecting a 28% year-over-year increase at constant exchange rates due to strong demand across various indications [7][12] Product Portfolio - Imfinzi has a broad global presence across multiple tumor types, including gastrointestinal cancers, non-small cell lung cancer, and bladder cancer, among others [9][10][11] - The drug is also approved for use in advanced or recurrent endometrial cancer in select markets [11]